grepcent public filings, reorganized for comparison

REYVOW — FDA application NDA211280

Application NDA211280 · type NDA · FDA status: approved · original approval 2019-10-11

Listed sponsor: ELI LILLY AND CO · LLY company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001REYVOWLASMIDITAN SUCCINATETABLETORALEQ 50MG BASEDiscontinuednot listedYes
002REYVOWLASMIDITAN SUCCINATETABLETORALEQ 100MG BASEDiscontinuednot listedYes
003REYVOWLASMIDITAN SUCCINATETABLETORALEQ 200MG BASEDiscontinuednot listedYes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

ListingProductDescriptive dateFlags/code
Patent 7423050001listed patent expiry date: 2028-02-17drug substance, drug product, U-1719
Patent 7423050002listed patent expiry date: 2028-02-17drug substance, drug product, U-1719
Patent 7423050003listed patent expiry date: 2028-02-17drug substance, drug product, U-1719
Patent 12257246001listed patent expiry date: 2030-07-07U-2718
Patent 12257246002listed patent expiry date: 2030-07-07U-2718
Patent 12257246003listed patent expiry date: 2030-07-07U-2718
Patent 11053214001listed patent expiry date: 2037-12-05drug substance, drug product, U-1719
Patent 11053214002listed patent expiry date: 2037-12-05drug substance, drug product, U-1719
Patent 11053214003listed patent expiry date: 2037-12-05drug substance, drug product, U-1719
Patent 12071423001listed patent expiry date: 2040-07-06drug product
Patent 12071423002listed patent expiry date: 2040-07-06drug product
NDA211280 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA211280 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA211280 FDA listing datesDescriptive regulatory dates only; no relationship to revenue or future sales is stated or implied.Source: Drugs@FDA and FDA Orange Book.Listed dateDated listing marker0.001.002.002019-10-111.002028-02-171.002030-07-071.002037-12-051.002040-07-061.00

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.